Jennison Associates LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 1.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 764,056 shares of the medical research company's stock after selling 7,906 shares during the period. Jennison Associates LLC owned about 0.58% of Natera worth $120,950,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Covestor Ltd increased its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after buying an additional 95 shares in the last quarter. Blue Trust Inc. grew its stake in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC increased its holdings in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock valued at $55,000 after acquiring an additional 106 shares in the last quarter. Hanseatic Management Services Inc. raised its position in Natera by 12.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock worth $158,000 after acquiring an additional 107 shares during the last quarter. Finally, Salem Investment Counselors Inc. lifted its holdings in shares of Natera by 0.7% in the fourth quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company's stock valued at $2,577,000 after purchasing an additional 110 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Natera Stock Down 1.3 %
Shares of NASDAQ NTRA traded down $2.32 during trading on Friday, reaching $172.82. 857,965 shares of the stock were exchanged, compared to its average volume of 1,331,850. The company has a market capitalization of $22.82 billion, a price-to-earnings ratio of -98.19 and a beta of 1.66. The business's 50-day moving average price is $167.56 and its 200 day moving average price is $140.02. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $67.33 and a twelve month high of $183.00.
Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm's revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.95) EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.56 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on NTRA shares. Leerink Partners raised their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Barclays assumed coverage on shares of Natera in a report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price on the stock. Sanford C. Bernstein lifted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. Finally, TD Cowen boosted their price objective on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and a consensus price target of $165.88.
Get Our Latest Stock Report on NTRA
Insider Activity at Natera
In other Natera news, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of the company's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 312,394 shares of company stock valued at $52,333,520. Insiders own 7.60% of the company's stock.
Natera Profile
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
